Analyst Ratings for [BCEL] Atreca, Inc.

6/4/21	Resumed	Outperform	X
BCEL Atreca Robert W. Baird
$30 $27
2/8/21	Initiated	Buy	X
BCEL Atreca Jefferies
$30
7/15/19	Initiated	Buy	X
BCEL Atreca Canaccord Genuity
$23
7/15/19	Initiated	Outperform	X
BCEL Atreca Cowen
7/15/19	Initiated	Outperform	X
BCEL Atreca Evercore ISI
7/15/19	Initiated	Buy	X
BCEL Atreca Stifel
$28

BCEL Atreca, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. Atreca, Inc. was founded in 2010 and is headquartered in Redwood City, California.